Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Use of Precision-Cut Lung Slices as an Ex Vivo Tool for Evaluating Viruses and Viral Vectors for Gene and Oncolytic Therapy.

Rosales Gerpe MC, van Vloten JP, Santry LA, de Jong J, Mould RC, Pelin A, Bell JC, Bridle BW, Wootton SK.

Mol Ther Methods Clin Dev. 2018 Aug 4;10:245-256. doi: 10.1016/j.omtm.2018.07.010. eCollection 2018 Sep 21.

2.

Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer.

Santry LA, McAusland TM, Susta L, Wood GA, Major PP, Petrik JJ, Bridle BW, Wootton SK.

Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191. doi: 10.1016/j.omtm.2017.10.004. eCollection 2018 Jun 15.

3.

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW.

J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. Review.

PMID:
29311387
4.

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.

Hummel J, Bienzle D, Morrison A, Cieplak M, Stephenson K, DeLay J, Woods JP, Lichty BD, Bridle BW.

Sci Rep. 2017 Nov 16;7(1):15738. doi: 10.1038/s41598-017-15992-4.

5.

Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission.

Mould RC, van Vloten JP, AuYeung AWK, Karimi K, Bridle BW.

Endocr Relat Cancer. 2017 Dec;24(12):T311-T329. doi: 10.1530/ERC-17-0316. Epub 2017 Sep 14. Review.

PMID:
28912377
6.

Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections.

Mould RC, AuYeung AWK, van Vloten JP, Susta L, Mutsaers AJ, Petrik JJ, Wood GA, Wootton SK, Karimi K, Bridle BW.

Sci Rep. 2017 Aug 16;7(1):8322. doi: 10.1038/s41598-017-08665-9.

7.

Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.

Allison KE, Coomber BL, Bridle BW.

Immunology. 2017 Oct;152(2):175-184. doi: 10.1111/imm.12777. Epub 2017 Jul 10. Review.

PMID:
28621843
8.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2016 Jun 1;196(11):4587-95. doi: 10.4049/jimmunol.1600106. Epub 2016 Apr 27.

9.

Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD.

Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25.

10.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines.

Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y.

Oncoimmunology. 2013 Aug 1;2(8):e26013. Epub 2013 Aug 27.

11.

Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation.

Kim JJ, Bridle BW, Ghia JE, Wang H, Syed SN, Manocha MM, Rengasamy P, Shajib MS, Wan Y, Hedlund PB, Khan WI.

J Immunol. 2013 May 1;190(9):4795-804. doi: 10.4049/jimmunol.1201887. Epub 2013 Apr 3.

12.

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, Wan Y.

Blood. 2013 Mar 28;121(13):2432-9. doi: 10.1182/blood-2012-06-438481. Epub 2013 Jan 16.

13.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.

Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.

14.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.

15.

ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC.

Mol Ther. 2012 Jun;20(6):1148-57. doi: 10.1038/mt.2011.301. Epub 2012 Jan 24.

16.

Neuroendocrine cancer vaccines in clinical trials.

Bridle BW.

Expert Rev Vaccines. 2011 Jun;10(6):811-23. doi: 10.1586/erv.11.68. Review.

PMID:
21692702
17.

Multi-stability and multi-instability phenomena in a mathematical model of tumor-immune-virus interactions.

Eftimie R, Dushoff J, Bridle BW, Bramson JL, Earn DJ.

Bull Math Biol. 2011 Dec;73(12):2932-61. doi: 10.1007/s11538-011-9653-5. Epub 2011 Apr 8.

PMID:
21476110
18.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15.

19.

Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.

Bridle BW, Li J, Jiang S, Chang R, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2010 Apr 15;184(8):4269-75. doi: 10.4049/jimmunol.0901447. Epub 2010 Mar 17.

20.

Combining oncolytic virotherapy and tumour vaccination.

Bridle BW, Hanson S, Lichty BD.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Review.

PMID:
20226716

Supplemental Content

Loading ...
Support Center